Atara Biotherapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 8.01 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 80.40M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. T...